Literature DB >> 16076942

Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women.

Debbie A Lawlor1, George Davey Smith, Shah Ebrahim, Claire Thompson, Naveed Sattar.   

Abstract

CONTEXT: Low adiponectin levels predict type 2 diabetes, and one prospective study in men reported its independent prediction of vascular events. Many observers thus already consider adiponectin to be a major part of the "common soil" underpinning diabetes and vascular disease.
OBJECTIVE: The objective of this study was to assess the association between adiponectin and incident coronary heart disease (CHD) risk in the British Women's Heart and Health Study.
DESIGN: This was a prospective (4 yr) case (n = 167) control (n = 334) study nested within the 4286 women in British Women's Heart and Health Study.
SETTING: The study was performed in a primary care setting. PARTICIPANTS: The study consisted of women (n = 4286) randomly selected from 23 British towns between 1999 and 2001, who were 60-79 yr of age at baseline. MAIN OUTCOME MEASURES: Association of adiponectin with CHD risk factors and incident CHD events were the main outcome measures.
RESULTS: Among both cases and controls, adiponectin positively correlated with age and high-density lipoprotein cholesterol and inversely correlated with waist to hip ratio, fasting insulin, fasting glucose, homeostasis model assessment of insulin resistance scores, C-reactive protein, and triglycerides. However, despite adequate power and these associations with CHD risk factors, adiponectin did not predict CHD events in unadjusted or adjusted analyses. The relative risk ratio for a doubling of adiponectin was 0.93 (95% confidence interval, 0.78, 1.11).
CONCLUSIONS: It is premature to consider adiponectin as a root for vascular disease in women despite its association with insulin resistance and diabetes. Additional prospective studies are required to determine whether there is a true sex difference in the effect of adiponectin on CHD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076942     DOI: 10.1210/jc.2005-0825

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  59 in total

1.  Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women.

Authors:  George A King; Sarah E Deemer; Dixie L Thompson
Journal:  Acta Diabetol       Date:  2010-05-08       Impact factor: 4.280

2.  Effects of sleep restriction on adiponectin levels in healthy men and women.

Authors:  Norah S Simpson; Siobhan Banks; Sylmarie Arroyo; David F Dinges
Journal:  Physiol Behav       Date:  2010-08-17

3.  Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women.

Authors:  Tobias Pischon; Frank B Hu; Cynthia J Girman; Nader Rifai; JoAnn E Manson; Kathryn M Rexrode; Eric B Rimm
Journal:  Atherosclerosis       Date:  2011-07-20       Impact factor: 5.162

Review 4.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

5.  Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men.

Authors:  Kerunne S Ketlogetswe; Wendy S Post; Xiuhong Li; Frank J Palella; Lisa P Jacobson; Joseph B Margolick; Lawrence A Kingsley; Mallory D Witt; Adrian S Dobs; Matthew J Budoff; Todd T Brown
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

6.  Emerging markers of atherosclerosis before and after bariatric surgery.

Authors:  Pimjai Anthanont
Journal:  Obes Surg       Date:  2015-05       Impact factor: 4.129

7.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.

Authors:  Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas
Journal:  Atherosclerosis       Date:  2006-10-02       Impact factor: 5.162

8.  Adiponectin and risk of vascular events in the Northern Manhattan study.

Authors:  Hannah Gardener; Ronald Goldberg; Armando J Mendez; Clinton B Wright; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco
Journal:  Atherosclerosis       Date:  2012-11-28       Impact factor: 5.162

9.  Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Authors:  Matthew R Smith; Hang Lee; Francis McGovern; Mary Anne Fallon; Melissa Goode; Anthony L Zietman; Joel S Finkelstein
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

10.  Total adiponectin and risk of symptomatic lower extremity peripheral artery disease in men.

Authors:  Michel M Joosten; Kaumudi J Joshipura; Jennifer K Pai; Monica L Bertoia; Eric B Rimm; Murray A Mittleman; Kenneth J Mukamal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-28       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.